Ascentage Pharma Group International - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AAPG Nasdaq 2836 www.ascentage.cn

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascentage Pharma Group International

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 - Nov 4th, 2026 4:30 pm
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London - Nov 3rd, 2026 5:30 am
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage - Oct 21st, 2026 10:30 am
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL - Oct 20th, 2026 5:30 pm
Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall - Oct 19th, 2026 1:14 pm
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - Oct 10th, 2026 8:35 am
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight - Oct 5th, 2026 8:55 am
Ascentage Pharma to Participate in Four Upcoming Investor Conferences - Sep 2nd, 2026 6:00 am
Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses - Aug 27th, 2026 11:07 pm
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary - Aug 21st, 2026 6:30 am
Ascentage Pharma Group International H1 Earnings Call Highlights - Aug 20th, 2026 9:04 am
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates - Aug 19th, 2026 5:00 pm
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit - Aug 13th, 2026 6:00 am
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 - Aug 5th, 2026 7:07 am
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 - Aug 5th, 2026 6:00 am
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer - Aug 2nd, 2026 5:30 pm
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know - Jul 27th, 2026 7:55 am
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - Jul 26th, 2026 5:30 pm
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% - Jul 9th, 2026 7:55 am
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development - Jun 30th, 2026 7:20 am